Walker 256 tumour growth causes marked changes of glutamine metabolism in rat small intestine

2002 ◽  
Vol 20 (2) ◽  
pp. 107-113 ◽  
Author(s):  
Manuela M. Ramos Lima ◽  
Maria Alice R. de Mello ◽  
Rui Curi
2019 ◽  
Vol 597 (15) ◽  
pp. 3905-3925 ◽  
Author(s):  
Veridiana Mota Moreira ◽  
Douglas Almeida ◽  
Claudinéia Conationi da Silva Franco ◽  
Rodrigo Mello Gomes ◽  
Kesia Palma‐Rigo ◽  
...  

1996 ◽  
Vol 14 (3) ◽  
pp. 187-192 ◽  
Author(s):  
Luiz Claudio Fernandes ◽  
Carlos Alberto Mattozo ◽  
Ubiratan Fabres Machado ◽  
Luis Fernando B. P. Costa Rosa ◽  
Rui Curi

Author(s):  
LUIZ CLAUDIO FERNANDES ◽  
CARLOS ALBERTO MATTOZO ◽  
UBIRATAN FABRES MACHADO ◽  
LUIS FERNANDO B. P. COSTA ROSA ◽  
RUI CURI

1991 ◽  
Vol 191 (1) ◽  
pp. 349-357 ◽  
Author(s):  
M. Plauth ◽  
A. Raible ◽  
D. Bauder-Groß ◽  
D. Vieillard-Baron ◽  
P. Fürst ◽  
...  

2017 ◽  
Vol 42 (1) ◽  
pp. 81-90 ◽  
Author(s):  
Claudinéia Conationi da Silva Franco ◽  
Carina Previate ◽  
Kátia Gama de Barros Machado ◽  
Silvano Piovan ◽  
Rosiane Aparecida Miranda ◽  
...  

Background/Aims: The sulphonylurea glibenclamide (Gli) is widely used in the treatment of type 2 diabetes. In addition to its antidiabetic effects, low incidences of certain types of cancer have been observed in Gli-treated diabetic patients. However, the mechanisms underlying this observation remain unclear. The aim of the present work was to evaluate whether obese adult rats that were chronically treated with an antidiabetic drug, glibenclamide, exhibit resistance to rodent breast carcinoma growth. Methods: Neonatal rats were treated with monosodium L-glutamate (MSG) to induce prediabetes. Control and MSG groups were treated with Gli (2 mg/kg body weight/day) from weaning to 100 days old. After Gli treatment, the control and MSG rats were grafted with Walker-256 tumour cells. After 14 days, grafted rats were euthanized, and tumour weight as well as glucose homeostasis were evaluated. Results: Treatment with Gli normalized tissue insulin sensitivity and glucose tolerance, suppressed fasting hyperinsulinaemia, reduced fat tissue accretion in MSG rats, and attenuated tumour growth by 27% in control and MSG rats. Conclusions: Gli treatment also resulted in a large reduction in the number of PCNA-positive tumour cells. Although treatment did improve the metabolism of pre-diabetic MSG-rats, tumour growth inhibition may be a more direct effect of glibenclamide.


2001 ◽  
Vol 120 (5) ◽  
pp. A183-A183
Author(s):  
H KOBAYASHI ◽  
H NAGATA ◽  
S MIURA ◽  
T AZUMA ◽  
H SUZUKI ◽  
...  

2008 ◽  
Vol 29 (S 1) ◽  
Author(s):  
K Nieber ◽  
S Michael ◽  
K Grötzinger ◽  
JW Rauwald ◽  
O Kelber

Diabetes ◽  
1993 ◽  
Vol 42 (8) ◽  
pp. 1126-1132 ◽  
Author(s):  
K. L. Madsen ◽  
V. M. Porter ◽  
R. N. Fedorak

Sign in / Sign up

Export Citation Format

Share Document